Skip to main content

*fontos, érdekes közlemény
1. EASL Clinical Practice Guidelines: Management of chronic hepatitis. B. J Hepatol. 2009, 50:227-242.
2. Lok A, McMahon BJ.: Chronic hepatitis B: Update 2009. Hepatology 2009, 50: 1-36.
3. Janssen HLA., Buster EHCJ.: Comments on the EASL practice guidelines for the management of
chronic hepatitis B: Controversies in interferon-based therapy. J Hepatol. 2009, 51:224-226.
4. Zoulim F, Locarnini S.: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009,
5. Liaw YF et al: 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic
hepatitis B. Gastroenterology 2009, 136:486-495.
6. Szerk. közl.: Hepatitis B: A “GLOBAL” health challenge. Gastroenterology 2009, 136:389-403.
7. van Bömmel F et al: Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected
patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51:73-80.
8. Moucari R et al: High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients
responding to interferon: a long-term follow-up study. J Hepatol. 2009, 50:1084-1092.
9. Shouval D et al: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued
succesful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009, 50:289-295.
10. Buster EHCJ et al: Factors that predict response of patients with hepatitis B e antigen-positive chronic
hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
11. Szerk. Közl.: Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold int
face of diminishing returns. Hepatology 2009, 49:1063-1065.
12. Brunetto MR et al: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon
alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
13. Moucari R et al: Early serum HBsAg drop: a strong predictor of sustained virological response to
pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
14. Szerk. közl.: Treatment of HBV/HCV coinfection: releasing the enemy within.
Gastroenterology 2009, 136:393-396.
15. Liu CJ et al: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with
hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.

16. Ploss, A. et al: Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.
Nature 457.7231 (2009): 882-86.
17. Mee, C. J. et al: Polarization Restricts Hepatitis C Virus Entry into HepG2 Hepatoma Cells. Journal of
Virology 83.12 (2009): 6211-21.
18. Sarasin-Filipowicz, M. et al: Decreased levels of microRNA miR-122 in individuals with hepatitis C
responding poorly to interferon therapy. Nature Medicine 15.1 (2009): 31-33.
19. Miyake, Y. et al: Meta-analysis: Reduced incidence of hepatocellular carcinoma in patients not
responding to interferon therapy of chronic hepatitis C. Int. J. Cancer: EPUB (2009): PMID 19957327.
20. Coulouarn, C. et al: Loss of miR-122 expression in liver cancer correlates with suppression of the
hepatic phenotype and gain of metastatic properties. Oncogene 28.40 (2009): 3526-36.
21. Bai, S. M. et al: MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells
and Sensitizes These Cells to Sorafenib. Journal of Biological Chemistry 284.46 (2009): 32015-27.
22. Kota, J. et al: Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer
Model. Cell 137.6 (2009): 1005-17.
23. Wang, K. et al: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings
of the National Academy of Sciences of the United States of America 106.11 (2009): 4402-07.
24. Yamamoto, Y. et al: MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma.
Biomarkers 14.7 (2009): 529-38.
25. Dienes HP et al: MicroRNA: New biomarkers in chronic liver disease. Global Antiviral J. 5:Suppl.1. p63-64.
26. Norman K.L. and Sarnow P.: Modulation of Hepatitis C virus RNA abundance and the isoprenoid
biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virology, 84 (2010):666-70.
27. Lanford E. R. et al: Therapeutic silencing of MicroRNA-122 in primates with Chronic Hepatitis C
Virus Infection. Nature 457.7231 (2009): 882-86.
28. Ghany MG et al: Diagnosis, management and treatment of hepatitis C: an update (AASLD practice
guidelines). Hepatology 2009, 49:1335-1360.
29. McHutchison JG et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
N Eng J Med 2009, 361:580-593.
30. Rumi MG.: Pegylated interferon alfa-2b versus pegylated interferon alfa-2a for chronic hepatitis C: The
unreached goal of superiority. J Hepatol 2009, 51:1097-1099.
31. Schulze zur Wiesch J, Lohse AW.: Results of the IDEAL trial: “Mirror, mirror on the wall…which’s the
fairest peginterferon of them all?” Hepatology 2009, 50:2034-2037.
32. Aghemo A, Colombo M.: Peginterferon alfa-2b versus peginterferon alfa-2a with ribavirin for the treatment
of chronic hepatitis C: The pursuit of an ideal. Gastroenterology 2010, 138:386-389.
33. McHutchison JG et al: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
New Eng J Med. 2009, 360:1827-1838.
34. Hézode C et al: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New
Eng J Med. 2009, 360:1839-1850.
35. Jensen DM et al: Retreatment of patients with chronic hepatitis C who do not respond to peginterferon
alfa-2b: a randomized trial. Ann. Intern Med 2009, 150:528-540.
36. Leise M, Kim WR.: Hepatitis C nonresponders: re-treat or retreat? Hepatology 2009, 50:1307-1309.
37. EASL practice guidelines: Management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.

38. Strassburg CP, Manns M.: Treatment of autoimmune hepatitis. Semin Liver Dis 2009, 29:273-285.
39. Aw MM et al: Mycophenolate mofetl as rescue treatment for autoimmune liver disease in children: A
5-year follow-up. J Hepatol 2009, 51:156-160.
40. Czaja AJ.: Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009,
41. Lindor KD et al: High-dose urosdeoxycholic acid for the treatment of primary sclerosing cholangitis.
Hepatology 2009, 50:808-814.
42. Chapman RW. Szerk. közl.: High-dose ursodeoxycholic acid in the treatment of primary sclerosing
cholangitis: Throwing the urso out with the bathwater? Hepatology 2009, 50:671-673.
43. Tanaka a et al: Vitamin D receptor polymorphisms are associated with increased susceptibility to
primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009, 50:1202-1209.
44. Adorini L.: Vitamin D receptor polymorphism in primary biliary cirrhosis: A functional connection?
J Hepatol 2009, 50:1071-1073.
45. Lee WM et al: Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure. Gastroenterology 2009, 137:856-864.
46. Koch A, Trautwein C.: N-acetylcystein on its way to a broader aplication in patients with acute liver
failure. Hepatology 2010, 51:338-340.
47. Argo CK et al: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.
J Hepatol 2009, 51:371-379.
48. Abid A et al: Soft drink consumption is associated with fatty liver disease independent of metabolic
syndrome. J Hepatol 2009, 51:918-924.
49. Dasarathy S et al: Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective
study. Hepatology 2009, 51:1061-1067.
50. Harrison SA et al: Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized,
prospective trial. Hepatology 2009, 49:80-86.
51. F.H. Cassidy, T. Yokoo, L. Aganovic, R.F. Hanna, M. Bydder, M.S. Middleton, G. Hamilton, A.D. Chavez,
J.B. Schwimmer and C.B. Sirlin:
Fatty Liver Disease: MR Imaging Techniques for the Detection and
Quantification of Liver Steatosis. RadioGraphics 2009;29:231-260.
52. R.J H. Borra, S. Salo, K. Dean, R. Lautamûki, P. Nuutila, M. Komu and R. Parkkola: Nonalcoholic Fatty
Liver Disease: Rapid Evaluation of Liver Fat Content with In-Phase and Out-of-Phase MR Imaging.
Radiology 2009;250:130-136.
53. T. Yokoo, M. Bydder, G. Hamilton, M.S. Middleton, A.C. Gamst, T. Wolfson, T. Hassanein, H.M. Patton,
J.E. Lavine, J.B. Schwimmer and C.B. Sirlin:
Nonalcoholic Fatty Liver Disease: Diagnostic and
Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T.
Radiology 2009;251:67-76.
54. G. d’Assignies, M. Ruel, A. Khiat, L. Lepanto, M. Chagnon, C. Kauffmann, An Tang, L. Gaboury and Y.
Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay
methods. Eur Radiol (2009) 19:2033-2040.
55. B. Guiu, R. Loffroy, J-M. Petit, S. Aho, D. Ben Salem, D. Masson, P. Hillon, J-P. Cercueil and D. Krause:
Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR
spectroscopy. Eur Radiol (2009) 19:2033-2040.
56. B. Guiu, J-M Petit, R. Loffroy, D. Ben Salem, S. Aho, D. Masson, P. Hillon, D. Krause and J-P. Cercueil
Quantification of Liver Fat Content:
Comparison of Triple-Echo Chemical Shift Gradient-Echo. Imaging

and in Vivo Proton MR Spectroscopy. Radiology 2009;250:95-102.
57. F. Staub, C. Tournoux-Facon, J. Roumy et al: Liver fibrosis staging with contrast-enhanced ultrasonography:
prospective multicenter study compared with METAVIR scoring. Eur Radiol (2009) 19:1991-1997.
58. K. Sandrasegaran, F.M. Akisik, Ch. Lin, B. Tahir, J. Rajan, R. Saxena and A.M. Aisen: Value of DiffusionWeighted MRI for Assessing Liver Fibrosis and Cirrhosis. AJR 2009; 193:1556-1560.
59. H. Chandarana, R.P. Lim, J.H. Jensen, C.H. Hajdu, M. Losada, J.S. Babb, S. Huffman and B. Taouli:
Hepatic Iron Deposition in Patients With Liver Disease: Preliminary Experience With Breath-Hold
Multiecho T2*-Weighted Sequence. AJR 2009; 193:1261-1267.
60. T.V. Bartolotta, A. Taibbi, M. Midiri and R. Lagalla: Focal liver lesions: contrast-enhanced ultrasound.
Abdom Imaging (2009) 34:193-209.
61. W. Luo, K. Numata, M. Morimoto, A. Nozaki, Y. Nagano, K. Sugimori and K. Tanaka: Three-Dimensional
Contrast-Enhanced Sonography of Vascular Patterns of Focal Liver Tumors: Pilot Study of Visualization
Methods. AJR 2009; 192:165-173.
62. A. Ba-Ssalamah, M. Uffmann, S. Saini, N. Bastati, Ch. Herold and W. Schima: Clinical value of MRI
liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal
liver lesions. Eur Radiol (2009) 19:342-357.
63. M.K. Seale, O.A. Catalano, S. Saini, P.F. Hahn and D.V. Sahani: Hepatobiliary-specific MR Contrast
Agents: Role in Imaging the Liver and Biliary Tree. RadioGraphics 2009;29:1725-1748.
64. E-S. Cho, J-S. Yu, J-H. Ahn, M-S. Park, J.H. Kim, J-J. Chung and K.W. Kim: Ferucarbotran-enhanced
T2-weighted magnetic resonance imaging: differentiation of hepatic cavernous hemangiomas from
malignant solid lesions. Abdom Imaging (2009) 34:494-501.
65. Christina Heilmaier, Amelie M. Lutz, Nicolae Bolog, Dominik Weishaupt, Burkhardt Seifert and Jürgen
K. Willmann:
Focal Liver Lesions: Detection and Characterization at Double-Contrast Liver MR Imaging with
Ferucarbotran and Gadobutrol versus Single-Contrast Liver MR Imaging. Radiology 2009;253: 724-733.
66. K.W. Doo, Ch.H. Lee, J.W. Choi, J. Lee, K.A. Kim and Ch.M. Park: “Pseudo Washout” Sign in High-Flow
Hepatic Hemangioma on Gadoxetic Acid Contrast-Enhanced MRI Mimicking Hypervascular Tumor.
AJR 2009; 193:W490-W496.
67. S.W. Anderson, J.B. Kruskal and R.A. Kane: Benign Hepatic Tumors and Iatrogenic Pseudotumors.
RadioGraphics 2009;29:211-229.
68. Villanueva C et al: Acute hemodynamic response to ß-blockers and prediction of long-term outcome
in primary prophylaxis of variceal bleeding. Gastroenterology 2009, 137:119-128.
69. La Mura et al: Prognostic value of acute hemodynamic response to i.v. propranolol in patients with
cirrhosis and portal hypertension. J Hepatol 2009, 51:279-287.
70. Tripathi D et al: Randomized controlled trial of carvedilol versus variceal band ligation for the
prevention of the first variceal bleed. Hepatology 2009, 50:825-833.
71. Bosch J, Garcia-Tsao G.: Pharmacological versus endoscopic therapy in the prevention of variceal
hemorrhage: and the winner is … Hepatology 2009, 50:674-677.
72. Kumar A et al: Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does
not reduce variceal rebleeding incidence. Gastroenterology 2009, 137:892-901.
73. Jalan R et al: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis
is associated with increased mortality. Hepatology 2009, 50:555-564.
74. Arroyo V.: Human serum albumin: Not just a plasma volume expander. Hepatology 2009, 50:355-357.
75. Hussai,K., El-Serag, H.B.: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.

Minerva Gastroenterol. Dietol., 2009, 55, 123-138.
76. Kojiro et al. International Consensus Group for Hepatocellular Neoplasia: Pathologic diagnosis of
early hepatocellular carcinoma: A report of the International Consensus Group for Hepatocellular
Neoplasia. Hepatology, 2009, 49, 658-664.
77. Mínguez, B., Tovar, V., Chiang, D. és mtsai: Pathogenesis of hepatocellular carcinoma and molecular
therapies. Curr. Opin. Gastroenterol., 2009, 25, 186-194.
78. Llovet, J.M., Bruix, J.: Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48,
79. Desmet, V.J.: East-West pathology agreement on precancerous liver lesions and early hepatocellular
carcinoma. Hepatology, 2009, 49, 355-357.
80. Nascimento, C., Caroli-Bottino, A., Paschoal, J.: Vascular immunohistochemical markers: contributions
to hepatocellular nodule diagnosis in explanted livers. Transplant. Proc., 2009, 41, 4211-4213.
81. Ohashi, M., Wakai, T., Korita, P.V.: Histological evalulation of intracapsular venous invasion for
discrimination between portal and hepatic venous invasion in hepatocellular carcinoma. J. Gastroenterol.
Hepatol., 2010, 25, 143-149.
82. Liu, S., Chan, K.W., Wang, G.: Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol., 2009,
104, 2617-2624.
83. Shirakawa, H., Suzuki, H., Shimomura, M.: Glypican-3 expression is correlated with poor prognosis in
hepatocellular carcinoma. Cancer Sci., 2009, 100, 1403-1407.
84. Nassar, A., Cohen, C., Siddiqui, M.T.: Utility of glypican-3 and survivin in differentiating hepatocellular
carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle
aspiration biopsies. Diagn. Cytopathol., 2009, 37, 629-635.
85. Tanaka, S., Arii, S.: Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci., 2009, 100, 1-8.
86. Ripoll C et al: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma
independently of severity of cirrhosis.
87. Marrero JA et al: α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early
hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
88. Forner A et al (szerk. közl): Alfa-fetoprotein for hepatocellular carcinoma diagnosis: The demise of a
brilliant star. Gastroenterology 2009,137:26-29.
89. Cho YK et al: Systematic review of randomized trials for hepatocellular carcinoma treated with
percutaneous ablation therapies. Hepatology 2009, 49:453-459.
90. N’Kontchou G et al: Radiofrequency ablation of hepatocellular carcinoma: long-term results and
prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009, 50:1475-1483.
91. Kitao, Y. Zen, O. Matsui, T. Gabata and Y. Nakanuma: Hepatocarcinogenesis: Multistep Changes of
Drainage Vessels at CT during Arterial Portography and Hepatic Arteriography-Radiologic-Pathologic
Correlation. Radiology 2009;252:605-614.
92. K. Ishigami, K. Yoshimitsu, Y. Nishihara, H. Irie, Y. Asayama, T. Tajima, A. Nishie, M. Hirakawa, Y.
Ushijima, D. Okamoto, A. Taketomi and H. Honda:
Hepatocellular Carcinoma with a Pseudocapsule on
Gadolinium-enhanced MR Images: Correlation with Histopathologic Findings. Radiology 2009;250:
93. H. Kim, M-S. Park, J.Y. Choi, Y.N. Park, M-J. Kim, K.S. Kim, J.S. Choi, K-H. Han, E. Kim and K.W. Kim:
Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol
(2009) 19:1744-1751.

A máj és epeutak, epehólyag 331

94. V. Vandecaveye, F. De Keyzer, Ch. Verslype, K. Op de Beeck, M. Komuta, B. Topal, I. Roebben, D. Bielen,
T. Roskams, F. Nevens and S. Dymarkowski:
Diffusion-weighted MRI provides additional value to
conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol
(2009) 19:2456-2466.
95. Ch. Schraml, N.F. Schwenzer, P. Martirosian, M. Bitzer, U. Lauer, C.D. Claussen and M. Horger:
Diffusion-Weighted MRI of Advanced Hepatocellular Carcinoma During Sorafenib Treatment: Initial
Results. AJR 2009; 193:W301-W307.
96. L. Mannelli, S. Kim, C.H. Hajdu, J.S. Babb, T.W.I. Clark and B. Taouli: Assessment of Tumor Necrosis
of Hepatocellular Carcinoma After Chemoembolization: Diffusion-Weighted and Contrast-Enhanced
MRI With Histopathologic Correlation of the Explanted Liver. AJR 2009; 193:1044-1052.
97. B.B. Frericks, Ch. Loddenkemper, A. Huppertz, S. Valdeig, A. Stroux, M. Seja, K-J. Wolf and Th. Albrecht:
Qualitative and Quantitative Evaluation of Hepatocellular Carcinoma and Cirrhotic Liver Enhancement
Using Gd-EOB-DTPA. AJR 2009; 193:1053-1060.
98. J-S. Yu, J-J. Chung, J.H. Kim and K.W. Kim: Small hypervascular hepatocellular carcinomas: value of
“washout” on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron
oxide-enhanced imaging. Eur Radiol (2009) 19:2614-2622.
99. D. Marin, M. Di Martino, A. Guerrisi, G. De Filippis, M. Rossi, S. Ginanni Corradini, R. Masciangelo,
C. Catalano and R. Passariello:
Hepatocellular Carcinoma in Patients with Cirrhosis: Qualitative
Comparison of Gadobenate Dimeglumine-enhanced MR Imaging and Multiphasic 64-Section CT.
Radiology 2009;251:85-95.
100. K.W. Kim, J.M. Lee, E. Klotz, H.S. Park, D.H. Lee, J.Y. Kim, S.J. Kim, S.H. Kim, J.Y. Lee, J.K. Han and
B.I. Choi:
Quantitative CT Color Mapping of the Arterial Enhancement Fraction of the Liver to Detect
Hepatocellular Carcinoma. Radiology 2009;250:425-434.
101. D. Marin, C. Catalano, G. De Filippis, M. Di Martino, A. Guerrisi, M. Rossi and R. Passariello: Detection
of Hepatocellular Carcinoma in Patients with Cirrhosis: Added Value of Coronal Reformations from
Isotropic Voxels with 64-MDCT. AJR 2009; 192:180-187.
102. Y.E. Chung, M-S. Park, Y.N. Park, H-J. Lee, J.Y. Seok, J-S. Yu and M-J. Kim: Hepatocellular Carcinoma
Variants: Radiologic-Pathologic Correlation. AJR 2009; 193:W7-W13.
103. D. Marin, R.C. Nelson, E. Samei, E.K. Paulson, L.M. Ho, D.T. Boll, D.M. DeLong, T.T. Yoshizumi and
S.T. Schindera:
Hypervascular Liver Tumors: Low Tube Voltage, High Tube Current Multidetector CT
during Late Hepatic Arterial Phase for Detection-Initial Clinical Experience. Radiology 2009;251:771-779.
104. Cescon M. és mtsai: A cirrhotikus máj HCC rezekciók mértékének megítélése a preoperatív adatok
alapján. Arch. Surg. 2009. Cescon M. és mtsai
105. Torzoli G et al: HCC szegmentális és szubszegmentális rezekciója (ultrahangvezérelt kompresszió)
Ann. Surg. 2009.
106. Peck-Radosavljevic M. és mtsai: Hepatocelluláris carcinoma Sorafenib kezelésének konszenzus javaslata.
Eur. J. Gastroenterol. Hepatol. 2010.
107. Palavecino M. és mtsai: HCC miatti kiterjesztett rezekció portalis véna embolizációval és anélkül.
Surgery 2009.
108. Edeline J, Raoul JL, Vauleon E, Guillygomac’h A, Boudjema K, Boucher E.: Systemic chemotherapy
for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroentero. 2009.
Feb 14;15(6):713-6.
109. Tsuchiya A, Imai M, Kamimura H, et al: Successful treatment of multiple lung metastases of hepatocellular
carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. World J Gastroenterol.
2009 Apr 14;15(14):1779-81.

332 Gastro Update 2010

110. Tandon P, Garcia-Tsao G.: Prognostic indicators in hepatocellular carcinoma: a systematic review of
72 studies. Liver Int. 2009 Apr;29(4):502-10. Epub 2008 Dec 24.
111. Farinati F, Sergio A, Baldan A, et al: Early and very early hepatocellular carcinoma: when and how much
do staging and choice of treatment really matter? A multi-center study. BMC Cancer. 2009 Jan 27;9:33.
112. Marin HL, Furth EE, Olthoff K, et al: Histopathologic outcome of neoadjuvant image-guided therapy
of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2009 Jun;18(2):169-76.
113. Hou YB, Chen MH, Yan K, et al: Adjuvant percutaneous radiofrequency ablation of feeding artery of
hepatocellular carcinoma before treatment. World J Gastroenterol. 2009 Jun 7;15(21):2638-43.
114. Kong WT, Zhang WW, Qiu YD, et al: Major complications after radiofrequency ablation for liver tumors:
analysis of 255 patients. World J Gastroenterol. 2009 Jun 7;15(21):2651-6.
115. Xiao EH, Guo D, Bian DJ.: Effect of preoperative transcatheter arterial chemoembolization on
angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol. 2009 Sep 28;15(36):4582-6.
116. Yang WZ, Jiang N, Huang N, et al: Combined therapy with transcatheter arterial chemoembolization
and percutaneous microwave coagulation for small hepatocellular carcinoma. World J Gastroenterol.
2009 Feb 14;15(6):748-52.
117. Choi SB, Kim KS, Park YN, et al: The efficacy of hepatic resection after neoadjuvant transarterial
chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size.
J Korean Med Sci. 2009 Apr;24(2):242-7.
118. Hwang JP, Hassan MM.: Survival and hepatitis status among Asian Americans with hepatocellular
carcinoma treated without liver transplantation. BMC Cancer. 2009 Feb 4;9:46.
119. Dagher I. és mtsai: Laparoszkópos kiterjesztett májrezekciók (a mûtéti standard fejlõdése). Ann. Surg. 2009.
120. Buell F.J., Cherqui D., Geller D.A., et al: The International Position on Laparoscopic Liver Surgery.
The Louisville Statement, 2008. Ann. Surg. 2009;250: 825-830.
121. Vigano L. és mtsai: A laparoscopos májresectio tanulási szakasza. Ann. Surg. 2009.
122. Ikeda M. Hasegawa K., Sano K. et al: The Vessel Sealing System (LigaSure) in Hepatic Resection. A
Randomized Controlled Trial. Ann. Surg. 2009;250: 199-203.
123. Richter, S.; Kollmar, O.; Schuld, J.; Moussavian, M. R.; Igna, D.; Schilling, M. K.: For the Chirurgische
Arbeitsgemeinschaft OP-Technik und OP-Strukturen (CAOP) of the Deutsche Gesellschaft fur Allgemeinund Viszeralchirurgie: Randomized clinical trial of efficacy and costs of three dissection devices in liver
resection. Br.J. Surg. 2009,96:593-601.
124. Fu S-Y. és mtsai: Májrezekció szelektív véna hepatika exkluzióval. Ann. Surg. 2009.
125. Cescon M., Vetrone G., Grazi G.L, et al: Trends in Perioperative Outcome After Hepatic Resection.
Analysis of 1500 Consecutive Unselected Cases Over 20 Years. Ann. Surg. 2009;249: 995-1002.
126. Stockmann M., Lock J.F., Riecke B., et al: Prediction of Postoperative Outcome After Hepatectomy
With a New Bedside Test for Maximal Liver Function Capacity. Ann.Surg. 2009. ;250: 119-125.
127. Slankamenac K. és mtsai.: A májrezekció utáni veseelégtelenség elõjelzésére alkalmas score rendszer.
Ann. Surg. 2009.
128. Yachida S.; Wakabayashi H.; Okano K.; Suzuki Y.: Prediction of posthepatectomy hepatic functional
reserve by serum hyaluronate. Br.J.Surg. 2009, 96:501-508.
129. Szijártó A, Hargitai B, Fischer S, Darvas, Kupcsulik P.: Two-Staged Procedure of Portal Ligation and
Hepatectomy Monitored by ICG Clearance. J. Invest. Surg. 2009,22:63-68.
130. K. Coenegrachts, F. De Geeter, L. ter Beek, N. Walgraeve, Sh. Bipat, J. Stoker and H. Rigauts: Comparison

334 Gastro Update 2010

of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of
colorectal liver metastases. Eur Radiol (2009) 19:370-379.
131. Ph.J.A. Robinson: The effects of cancer chemotherapy on liver imaging. Eur Radiol (2009) 19:1752-1762.
132. K.S. Jhaveri, J. Halankar, D. Aguirre, M. Haider, G. Lockwood, M. Guindi and S. Fischer: Intrahepatic
Bile Duct Dilatation Due to Liver Metastases From Colorectal Carcinoma. AJR 2009; 193:752-756.
133. M. Mantatzis, S. Kakolyris, K. Amarantidis, A. Karayiannakis and P. Prassopoulos: Treatment response
classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements
accurate? Eur Radiol (2009) 19:1809-1816.
134. Castaing D. és mtsai: Laparoszkópos és nyitott májrezekciók colorectális májáttétek esetén.
Ann. Surg. 2009.
135. Yong M.C. és mtsai: A kolorektális májáttétek sebészi eltávolítása utáni recidíva. Ann. Surg. 2009.
136. Homayounfar K. és mtsai: Kétlépcsõs májrezekció portalis ligatura után-a bilobaris májáttétek kurativ
kezelése Int J Colorectal Dis 2009.
137. Oussoultzoglou E. és mtsai: A colorectalis májmetastasis resectiója a májhílus nyirokcsomói érintettsége
esetén az új chemotherápiás kezelések mellett. Ann. Surg. 2009.
138. Brachet D. és mtsai: A recidív colorectalis májáttét miatti ismételt májrezekciók prognosztikai tényezõi:
62 eset egy intézetbõl. Dis. Colon&, Rectum 2009.
139. van der Bij és mtsai: A perioperatív idõszakot a kolorektális daganatok esetében kevéssé értékelik.
Ann. Surg. 2009.
140. Pamecha V. és mtsai: A PVE hatása a kolorektális májáttét növekedésében. Br.J.Cancer 2009.
141. Pamecha V. és mtsai: A porta embolizció utáni túlélés és tumor recidíva kolorektális májáttétek esetén.
Ann. Surg Oncol. 2009.
142. Ayiomamitis GD és mtsai: Laparoscopos jobboldali véna portae lekötés a májrezekciók elõkészítésében.
Adv. Surg. Techniques 2009.
143. Vogl TJ, Gruber T, Balzer JO, et al: Repeated transarterial chemoembolization in the treatment of liver
metastases of colorectal cancer: prospective study. Radiology. 2009 Jan;250(1):281-9.
144. Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al: Comparing safety and efficacy of first-line irinotecan/
fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer:
findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009 Jun
145. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al: Radioembolization of colorectal hepatic metastases
using yttrium-90 microspheres. Cancer. 2009 May 1;115(9):1849-58.
146. Masi G, Loupakis F, Pollina L, et al: Long-term outcome of initially unresectable metastatic colorectal
cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)
followed by radical surgery of metastases. Ann. Surg. 2009 Mar;249(3):420-5.
147. Messick CA, Sanchez J, Dejulius KL, et al: Genetic and molecular diversity of colon cancer hepatic
metastases. Surgery. 2009 Aug;146(2):227-31.
148. Brouquet A, Benoist S, Julie C, et al: Risk factors for chemotherapy-associated liver injuries: A multivariate
analysis of a group of 146 patients with colorectal metastases. Surgery. 2009 Apr;145(4):362-71. Epub
2009 Feb 23.
149. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 2009 Feb 5;360(6):563-72.

150. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R,
Bodoky G, et. al:
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med. 2009 Apr 2;360(14):1408-17.
151. Hur H, Ko YT, Min BS, et al: Comparative study of resection and radiofrequency ablation in the treatment
of solitary colorectal liver metastases. Am J Surg. 2009 Jun;197(6):728-36.
152. Bouchahda M, Adam R, Giacchetti S, et al: Rescue chemotherapy using multidrug chronomodulated
hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009
Nov 1;115(21):4990-9.
153. Katoh H, Yamashita K, Sato T, et al: Prognostic significance of peritoneal tumour cells identified at
surgery for colorectal cancer. Br J Surg. 2009 Jul;96(7):769-77.
154. Oussoultzoglou E, Romain B, Panaro F, et al: Long-term survival after liver resection for colorectal
liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy
regimens. Ann. Surg. 2009 Jun;249(6):879-86.
155. Cucchetti A,.Ercolani G, Vivarelli M, et al: Is Portal Hypertension a Contraindication to Hepatic Resection?
Ann. Surg. 2009;250: 922-928.
156. Hwang S., Lee S-G., Ko G-Y., et al: Sequential Preoperative Ipsilateral Hepatic Vein Embolization
After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary
Malignancy. Ann. Surg. 2009;249: 608-616.
157. Cotroneo A.R Innocenti P Marano G Legnini M Iezzi R.: Pre-hepatectomy portal vein embolization:
Single center experience. EJSO 2009,35: 71-78.
158. van den Esschert J W et al: A máj regeneratioja PVE utáni májreseciot követõen. J. Gastrointest. Surg. 2009.
159. Tashiro S. Et al: Mechanism of liver regeneration after liver resection and portal vein embolization
(ligation) is different? J Hepatobiliary Pancreat Surg. 2009: 16:292-299.
160. Sugimoto T. Yamada T. Iwata H. Sekino T. Matsumoto S. Ishida N. Manabe H. Kimura M. Takemura H:
Two-Stage Portal Vein Ligation Facilitates Liver Regeneration in Rats. Eur Surg. Res 2009;42:181-188.
161. de Graaf W, van den Esschert J W,van Lienden K P, van Gulik T M.: Induction of Tumor Growth After
Preoperative Portal Vein Embolization: Is It a Real Problem? Ann. Surg. Oncol 2009, 16:423-430.
162. Barbaro B., Caputo F., Tebala C., Di Stasi C, Vellone M., Giuliante F., Nuzzo G. Bonomo L.: Preoperative
right portal vein embolisation: indications and results. Radiol med 2009, 114:553-570.
163. Reiner CS; Karlo C; Petrowsky H; Marincek B; Weishaupt; Frauenfelder T.: Preoperative Liver Volumetry:
How Does the Slice Thickness Influence the Multidetector Computed Tomography- and Magnetic
Resonance-Liver Volume Measurements? J. Comp. Ass.Tomography. 2009,33:390-397.
164. Lin K-J; Liao C-H; Hsiao I-T; Yen T-C; Chen T-C; Jan Y-Y; Chen M-F; Yeh T-S.: Improved hepatocyte
function of future liver remnant of cirrhotic rats after portal vein ligation: A bonus other than volume
shifting. Surgery. 2009,145:202-211.
165. Schwartz, J.J. Hutson, W.R. Gayowski ,T.J. et al: Liver Transplantation for Cholangiocarcinoma.
Transplantation 2009;88: 295-298.
166. Heimbach, J.: Hilar Cholangiocarcinoma and Liver Transplantation. Transplantation 2009;88: 299-300.
167. Jain, A. Fiaz, O. Baber, S. et al: Recurrent Nonhepatic and De Novo Malignancies After Liver
Transplantation. Transplantation 2009;88: 706-710.
168. Hwang, S. Lee, S. Belghiti,J.: Liver transplantation for HCC: its role. Eastern and Western perspectives
J Hepatobiliary Pancreat Surg. DOI 10.1007/s00534-009-0241-0.
169. Scatton, O. Liddo, G. Beghiti, J.: Liver transplantation or hepatocellular carcinoma: curent topcs in France.

J Hepatobiliary Pancreat Surg. DOI 10.1007/s00534-009-0164-9.
170. Laurent, A. Tayar, C.Andreoletti, M. et al: Laparoscopic liver resection facilitates salvage liver
transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 200) 16:310-314.
171. Lewandowski, R.J. Kulik, L.M.Riaz,A et al: A Comparative Analysis of Transarterial Downstaging for
Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization. American Journal of
Transplantation 2009; 9: 1920-192.
172. Lee, P. Lee, S. Bussutil, R.: Is Downstaging Prior to Liver Transplantation Important in Hepatocellular
Carcinoma? American Journal of Transplantation 2009; 9: 1703-1704.
173. Wong, R.J. Corley D.A.: Survival Differences by Race/Ethnicity and Treatment for Localized Hepatocellular
Carcinoma Within the United States. Dig Dis Sci (2009) 54:2031-2039.
174. Kempema,L. Höckerstedt, K.: Treatment of polycystic liver disease. British Journal of Surgery 2009;
96: 1379-1380.
175. Verna, E.C. DeMartin, E. Burra,P. et al: The Impact of Hepatitis C and Biliary Complications on
Patient and Graft Survival Following Liver Transplantation. American Journal of Transplantation 2009; 9:
176. Watt, K. Veldt, B.Charlton, M.: A Practical Guide to the Management of HCV Infection Following Liver
Transplantation. American Journal of Transplantation 2009; 9: 1707-1713.
177. Herreros de Tejada A, Calleja JL, Díaz G, Pertejo V, Espinel J, Cacho G, Jiménez J, Millán I, García F,
Abreu L; UDOGUIA-04 Group.:
Double-guidewire technique for difficult bile duct cannulation: a
multicenter randomized, controlled trial. Gastrointest Endosc. 2009 Oct;70(4):700-9. *****
178. Cennamo V, Fuccio L, Zagari RM, Eusebi LH, Ceroni L, Laterza L, Fabbri C, Bazzoli F.: Can a wire-guided
cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A
meta-analysis of randomized controlled trials. Am J Gastroenterol. 2009 Sep;104(9):2343-50. ****
179. Bourke MJ, Costamagna G, Freeman ML.: Biliary cannulation during endoscopic retrograde
cholangiopancreatography: core technique and recent innovations. Endoscopy. 2009 Jul;41(7):612-7.
Epub 2009 Jul 8. Review. ****
180. Madácsy L, Kurucsai G, Fejes R, Székely A, Székely I.: Prophylactic pancreas stenting followed by
needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new
method to prevent post-ERCP pancreatitis. Dig Endosc. 2009 Jan;21(1):8-13. ***
181. Paspatis GA, Chainaki I, Manolaraki MM, Vardas E, Theodoropoulou A, Tribonias G, Konstantinidis K,
Karmiris K, Chlouverakis G.:
Efficacy of bispectral index monitoring as an adjunct to propofol deep
sedation for ERCP: a randomized controlled trial. Endoscopy. 2009 Dec;41(12):1046-51. ***
182. Varadarajulu S, Christein JD, Tamhane A, Drelichman ER, Wilcox CM.: Prospective randomized trial
comparing EUS and EGD for transmural drainage of pancreatic pseudocysts (with videos). Gastrointest
Endosc. 2008 Dec;68(6):1102-11. ****
183. Gardner TB, Chahal P, Papachristou GI, Vege SS, Petersen BT, Gostout CJ, Topazian MD, Takahashi N,
Sarr MG, Baron TH.:
A comparison of direct endoscopic necrosectomy with transmural endoscopic
drainage for the treatment of walled-off pancreatic necrosis. Gastrointest Endosc. 2009 May;69(6):
1085-94. ****
184. Mutignani M, Iacopini F, Perri V, Familiari P, Tringali A, Spada C, Ingrosso M, Costamagna G.:
Endoscopic gallbladder drainage for acute cholecystitis: technical and clinical results. Endoscopy. 2009
Jun;41(6):539-46. ***
185. Barkay O, Bucksot L, Sherman S.: Endoscopic transpapillary gallbladder drainage with the SpyGlass
cholangiopancreatoscopy system. Gastrointest Endosc. 2009 Nov;70(5):1039-40. *

186. Han J, Moon JH, Koo HC, Kang JH, Choi JH, Jeong S, Lee DH, Lee MS, Kim HG.: Effect of biliary
stenting combined with ursodeoxycholic acid and terpene treatment on retained common bile duct
stones in elderly patients: a multicenter study. Am J Gastroenterol. 2009 Oct;104(10):2418-21. ***
187. Eickhoff A, Koberstein S, Rothsching M, Gemmel C, Eickhoff JC, Riemann JF, Enderle MD.: Fragmentation
of bile duct stones: a prospective systematic in vitro evaluation of argon plasma coagulation, cryotechnology,
and water-jet technology. Endoscopy. 2009 Aug;41(8):702-6. *
188. Cho YD, Cheon YK, Moon JH, Jeong SW, Jang JY, Lee JS, Shim CS.: Clinical role of frequency-doubled
double-pulsed yttrium aluminum garnet laser technology for removing difficult bile duct stones (with
videos). Gastrointest Endosc. 2009 Oct;70(4):684-9. *
189. Artifon EL, Kumar A, Eloubeidi MA, Chu A, Halwan B, Sakai P, Bhutani MS.: Prospective randomized
trial of EUS versus ERCP-guided common bile duct stone removal: an interim report (with video).
Gastrointest Endosc. 2009;69(2):238-43. ***
190. van Santvoort HC, Besselink MG, de Vries AC, Boermeester MA, Fischer K, Bollen TL, Cirkel GA,
Schaapherder AF, Nieuwenhuijs VB, van Goor H, Dejong CH, van Eijck CH, Witteman BJ, Weusten BL,
van Laarhoven CJ, Wahab PJ, Tan AC, Schwartz MP, van der Harst E, Cuesta MA, Siersema PD, Gooszen
HG, van Erpecum KJ; Dutch Acute Pancreatitis Study Group.:
Early endoscopic retrograde
cholangiopancreatography in predicted severe acute biliary pancreatitis: a prospective multicenter study.
Ann. Surg. 2009 Jul;250(1):68-75. *****
191. Arvanitakis M, Hookey L, Tessier G, Demetter P, Nagy N, Stellke A, De Maertelaer V, Deviere J, Le
Moine O.:
Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography
for investigation of biliary strictures. Endoscopy. 2009 Aug;41(8):696-701. **
192. Kawakami H, Kuwatani M, Etoh K, Haba S, Yamato H, Shinada K, Nakanishi Y, Tanaka E, Hirano S,
Kondo S, Kubota K, Asaka M.:
Endoscopic retrograde cholangiography versus peroral cholangioscopy
to evaluate intraepithelial tumor spread in biliary cancer. Endoscopy. 2009 Nov;41(11):959-64.*
193. Fishman DS, Tarnasky PR, Patel SN, Raijman I.: Management of pancreaticobiliary disease using a new
intra-ductal endoscope: the Texas experience. World J Gastroenterol. 2009 Mar 21;15(11):1353-8. ***
194. Yoon WJ, Ryu JK, Yang KY, Paik WH, Lee JK, Woo SM, Park JK, Kim YT, Yoon YB.: A comparison of metal
and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an
emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc. 2009 Aug;
70(2):284-9. **
195. Ornellas LC, Stefanidis G, Chuttani R, Gelrud A, Kelleher TB, Pleskow DK.: Covered Wallstents for
palliation of malignant biliary obstruction: primary stent placement versus reintervention. Gastrointest
Endosc. 2009 Oct;70(4):676-83.**
196. Naitoh I, Ohara H, Nakazawa T, Ando T, Hayashi K, Okumura F, Okayama Y, Sano H, Kitajima Y, Hirai M,
Ban T, Miyabe K, Ueno K, Yamashita H, Joh T.:
Unilateral versus bilateral endoscopic metal stenting
for malignant hilar biliary obstruction. J Gastroenterol Hepatol. 2009 Apr;24(4):552-7. **
197. Loew BJ, Howell DA, Sanders MK, Desilets DJ, Kortan PP, May GR, Shah RJ, Chen YK, Parsons WG,
Hawes RH, Cotton PB, Slivka AA, Ahmad J, Lehman GA, Sherman S, Neuhaus H, Schumacher BM.:
Comparative performance of uncoated, self-expanding metal biliary stents of different designs in 2
diameters: final results of an international multicenter, randomized, controlled trial. Gastrointest Endosc.
2009 Sep;70(3):445-53. ****
198. Yang KY, Ryu JK, Seo JK, Woo SM, Park JK, Kim YT, Yoon YB.: A comparison of the Niti-D biliary
uncovered stent and the uncovered Wallstent in malignant biliary obstruction. Gastrointest Endosc. 2009
Jul;70(1):45-51. *
199. Park do H, Koo JE, Oh J, Lee YH, Moon SH, Lee SS, Seo DW, Lee SK, Kim MH.: EUS-guided biliary
drainage with one-step placement of a fully covered metal stent for malignant biliary obstruction: a

prospective feasibility study. Am J Gastroenterol. 2009 Sep;104(9):2168-74. ***
200. Mahajan A, Ho H, Sauer B, Phillips MS, Shami VM, Ellen K, Rehan M, Schmitt TM, Kahaleh M.:
Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: midterm
evaluation (with video). Gastrointest Endosc. 2009 Aug;70(2):303-9. **
201. Behm B, Brock A, Clarke BW, Ellen K, Northup PG, Dumonceau JM, Kahaleh M.: Partially covered
self-expandable metallic stents for benign biliary strictures due to chronic pancreatitis. Endoscopy.
2009 Jun;41(6):547-51.**
202. Liao Z, Li ZS, Wang W, Ye Z, Lai XW, Wang XT, Zou DW.: Endoscopic placement of a covered selfexpandable metal stent in the minor papilla in patients with chronic pancreatitis and pancreas divisum.
Endoscopy. 2009;41 Suppl 2:E302-3.*
203. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J.: Risk factors for complications after ERCP: a
multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009 Jul;70(1):80-8. *****
204. Manes G, Di Giorgio P, Repici A, Macarri G, Ardizzone S, Porro GB.: An analysis of the factors
associated with the development of complications in patients undergoing precut sphincterotomy: a prospective,
controlled, randomized, multicenter study. Am J Gastroenterol. 2009 Oct;104(10):2412-7.*****
205. Székely A., Kurucsai G., Bíró E., Joó I., Fejes R., Madacsy L.: Needle-knife precut access papillotomy
versus persistence in standard techniques for difficult bile duct cannulation and sphincterotomy. 2000,
UEGW, OP-E-104*, online:
206. Madácsy L, Kurucsai G, Fejes R, Székely A, Székely I.: Prophylactic pancreas stenting followed by
needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new
method to prevent post-ERCP pancreatitis. Dig Endosc. 2009 Jan;21(1):8-13.**
207. Lawrence C, Romagnuolo J, Cotton PB, Payne KM, Hawes RH.: Post-ERCP pancreatitis rates do not
differ between needle-knife and pull-type pancreatic sphincterotomy techniques: a multiendoscopist
13-year experience. Gastrointest Endosc. 2009 Jun;69(7):1271-5. *
208. Bai Y, Xu C, Yang X, Gao J, Zou DW, Li ZS.: Glyceryl trinitrate for prevention of pancreatitis after endoscopic
retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled
trials. Endoscopy. 2009 Aug;41(8):690-5. **
209. Madácsy L, Kurucsai G, Joó I, Gódi S, Fejes R, Székely A.: Rescue ERCP and insertion of a small-caliber
pancreatic stent to prevent the evolution of severe post-ERCP pancreatitis: a case-controlled series.
Surg. Endosc. 2009 Aug;23(8):1887-93. ****
210. Madácsy L, Fejes R, Kurucsai G, Joó I, Székely A, Bertalan V, Szepes A, Lonovics J.: Characterization
of functional biliary pain and dyspeptic symptoms in patients with sphincter of Oddi dysfunction: effect
of papillotomy. World J Gastroenterol. 2006 Nov 14;12(42):6850-6.**
211. Draganov PV, Kowalczyk L, Forsmark CE.: Prospective trial comparing solid-state catheter and waterperfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest
Endosc. 2009 Jul;70(1):92-5. ****
212. Testoni PA, Mangiavillano B, Mariani A, Carrara S, Notaristefano C, Arcidiacono PG.: Investigation
of Oddi sphincter structure by optical coherence tomography in patients with biliary-type 1 dysfunction:
a pilot in vivo study. Dig Liver Dis. 2009 Dec;41(12):907-12. **
213. Cheon YK, Cho YD, Moon JH, Im HH, Jung Y, Lee JS, Lee MS, Shim CS.: Effects of vardenafil, a
phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary
sphincter of Oddi dysfunction. Gastrointest Endosc. 2009 May;69(6):1111-6. ***
214. Affronti J.: Levitra for sphincter of Oddi dysfunction? Are you kidding? Gastrointest Endosc. 2009

215. Nuzzo G, Giuliante F, Giovannini I et al: Advantages of multidisciplinary management of bile duct
injuries occurring during cholecystectomy. Am J Surg. 2008;195:763-9.
216. Babel N, Sakpal SV, Paragi P et al: Iatrogenic Bile Duct Injury Associated with Anomalies of the Right
Hepatic Sectoral Ducts:
A Misunderstood and Underappreciated Problem. HPB Surgery 2009;
217. Jablonska B, Lampe P. Iatrogenic bile duct injuries: Etiology, diagnosis and management. World J
Gastroenterol 2009;15(33):4097-4104 nn
218. Jablonska B et al: Hepaticojejunostomy vs. End-to-end Biliary Reconstructions in the Treatment of
iatrogenic Bile Duct Injuries. J Gastrointest Surg. 2009;13:1084-1093.
219. Pinkas H, Brady PG: Biliary leaks after laparoscopic cholecystectomy: time to stent or time to drain.
Hepatobiliary pancreat Dis Int 2008;7:628-632.
220. Trentini EA, Crema E, Llanos JC et al: Biliary tract reconstruction using jejunal tube: an experimental
study in dogs. Hepatobiliary Pancreat Dis Int 2009;8:179-185.
221. Ghazal AH, Sorour MA, El-Riwini M, El-Bahrawy H: Single-step treatment of gall bladder and bile duct
stones: A combined endoscopic-laparoscopic technique. Int J Surg. 2009; doi:10.1016/j.ijsu. 2009.05.05.
222. Aimoto T, Uchida E, Fujita I et al: Early Surgical Management for Periampullary Retroperitoneal
Perforation Caused by Endoscopic Sphincterotomy: A Report of a Case. J Nippon Med Sch 2008;75
223. Shojaiefard A, Esmaeilzadeh M, Ghafouri A, Mehrabi A: Various Techniques for the Surgical Treatment
of Common Bile Duct Stones: A Meta Review. Gastroenterology Research and Practice 2009;
224. * Gurusamy KS, Samraj K: Primary closure versus T-tube drainage after common bile duct exploration
225. Ambreen M, Shaikh AR, Jamal A et al: Primary Closure Versus T-tube Drainage After Open Choledochotomy.
Asian J Surg. 2009;32(1):21-25.
226. van der Gaag N et al: Preoperative biliary drainage for periampullary tumors causing obstructive jaundice;
Drainage vs. (direct) Operation (DROP-trial). BMC Surgery doi:10.1186/1471-2482-7-3.
227. Abdullah SA, Gupta T, Jaafar AK et al: Ampullary carcinoma: Effect of periampullary biliary drainage
on surgical outcome. World J Gastroenterology 2009;15(23):2908-2912.
228. Ustundag Y, Bayraktar Y: Cholangiocarcinoma: A compact review of the literature. World J
Gastroenterology 2008;14(42):6458-6466.
229. Thomas H, Heaton ND: Late recurrence after surgery for cholangiocarcinoma: implications for follow-up?
Hepatobiliary Pancreat Dis Int 2008;7:544-546.
230. * Aljiffry M, Walsh MJ, Molinary M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma:
1990-2009. World J Gastroenterology 2009;15(34):4240-4262; http:///
231. Funabiki T, Matsubara T, Miyakawa A, Ishihara S: Pancreatobiliary maljunction and carcinogenesis to
biliary and pancreatic malignancy. Langenbecks Arch Surg 2009;394:159-169.
232. Watanabe M, Midorikawa Y, Yamano T et al: Carcinoma of the papilla of Vater following treatment of
pancreaticobiliary maljunction. World J Gastroenterology 2009;15(48):6126-6128.
233. Morris-Stiff G, Teli M, Jardine N, Puntis MCA: Ca19-9 antigen levels can distinguish between benign
and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009;8:620-626.
234. Jarayaman S, Davies W, Schlachta CM: Getting started with robotics in general surgery with cholecystectomy:

the Canadian experience. Can J Surg 2009;52(5):374-378.
235. Gurusamy KS, Samraj K, Fusai G, Davidson BR: Robot assistant for laparoscopic cholecystectomy.
Cochrane Database Syst Rev 2009;1:CD006578.
236. Huang J, Chang C, Wang J et al: Natiowide epidemiological study of severe gallstone disease in Taiwan.
BMC Gastroenterology 2009; doi:10.1186/1471-230X-9-63.
237. * Sandzén B, Rosenmüller M, Haapamaki MM et al: First attack of acut pancreatitis in Sweden 1988-2003:
incidence, aetiological classification, procedures and mortality – a register study. BMC Gastroenterology
2009; doi:10.1186/1471-230X/9/18.
238. Sandzén B, Haapamaki M, Nilson E et al: Cholecystectomy and sphincterotomy in patients with mild
acute biliary pancreatitis in Sweden 1988-2003: a nationwide register study. BMC Gastroenterology
2009; doi:10.1186/1471-230X-9-80.
239. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M.: Evidence-based approach to
cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009 Jan; 208(1):
134-47. Epub 2008 Oct 31. Review.
240. Aljiffry M, Walsh MJ, Molinari M.: Advances in diagnosis, treatment and palliation of cholangiocarcinoma:
1990-2009. World J Gastroenterol. 2009 Sep 14;15(34):4240-62. Review.
241. Fuller CD, Wang SJ, Choi M, Czito BG, Cornell J, Welzel TM, McGlynn KA, Luh JY, Thomas CR Jr.:
Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.
Cancer. 2009 Nov 15;115(22):5175-83.
242. Ito F, Cho CS, Rikkers LF, Weber SM.: Hilar cholangiocarcinoma: current management. Ann. Surg.
2009 Aug;250(2):210-8. Review.
243. Jonas S, Thelen A, Benckert C, Biskup W, Neumann U, Rudolph B, Lopez-Häänninen E, Neuhaus P. :
Extended liver resection for intrahepatic cholangiocarcinoma: A comparison of the prognostic accuracy
of the fifth and sixth editions of the TNM classification. Ann. Surg. 2009 Feb;249(2):303-9.
244. Nuzzo G, Giuliante F, Ardito F, Giovannini I.: Intrahepatic cholangiocarcinoma. Ann. Surg. 2009 Mar;
249(3):541-2; author reply 542.
245. Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R, Gruenberger T.: Lymph
node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg. 2009 Aug;96(8):919-25.